 Amy Keating
Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptor Protein-Tyrosine Kinases | 13 | 2016 | 282 | 2.470 |
Why?
| | Hematopoietic Stem Cell Transplantation | 14 | 2021 | 572 | 2.420 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2023 | 280 | 2.030 |
Why?
| | Proto-Oncogene Proteins | 12 | 2016 | 726 | 1.810 |
Why?
| | Glioblastoma | 5 | 2016 | 256 | 1.500 |
Why?
| | Receptors, Antigen, T-Cell | 8 | 2023 | 629 | 0.960 |
Why?
| | Antibodies, Bispecific | 2 | 2021 | 29 | 0.960 |
Why?
| | Leukemia, Myeloid, Acute | 5 | 2021 | 509 | 0.920 |
Why?
| | Neoplasm, Residual | 2 | 2019 | 93 | 0.780 |
Why?
| | Stem Cell Transplantation | 2 | 2019 | 151 | 0.740 |
Why?
| | Transplantation Conditioning | 6 | 2021 | 181 | 0.710 |
Why?
| | Brain Neoplasms | 4 | 2017 | 1000 | 0.690 |
Why?
| | Poverty | 1 | 2021 | 464 | 0.640 |
Why?
| | Tissue Donors | 1 | 2019 | 356 | 0.610 |
Why?
| | c-Mer Tyrosine Kinase | 11 | 2016 | 58 | 0.600 |
Why?
| | Homocystinuria | 2 | 2019 | 59 | 0.580 |
Why?
| | Immunotherapy, Adoptive | 6 | 2022 | 184 | 0.570 |
Why?
| | Antineoplastic Agents | 7 | 2021 | 2062 | 0.530 |
Why?
| | Graft vs Host Disease | 4 | 2021 | 232 | 0.530 |
Why?
| | Transplantation, Heterologous | 1 | 2014 | 206 | 0.520 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 263 | 0.510 |
Why?
| | Protein Kinase Inhibitors | 5 | 2016 | 889 | 0.510 |
Why?
| | RNA, Small Interfering | 5 | 2014 | 605 | 0.510 |
Why?
| | Anilides | 1 | 2014 | 80 | 0.510 |
Why?
| | Quinolines | 1 | 2014 | 141 | 0.480 |
Why?
| | Child | 25 | 2023 | 18757 | 0.450 |
Why?
| | Carcinogenesis | 1 | 2013 | 172 | 0.450 |
Why?
| | Central Nervous System | 1 | 2013 | 256 | 0.430 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2022 | 56 | 0.430 |
Why?
| | Cell Movement | 3 | 2014 | 936 | 0.430 |
Why?
| | Cystathionine beta-Synthase | 1 | 2011 | 62 | 0.420 |
Why?
| | Pediatrics | 1 | 2019 | 1057 | 0.410 |
Why?
| | Unrelated Donors | 3 | 2019 | 42 | 0.400 |
Why?
| | Chemokines | 1 | 2011 | 242 | 0.390 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2013 | 456 | 0.380 |
Why?
| | Astrocytoma | 1 | 2010 | 111 | 0.380 |
Why?
| | Cord Blood Stem Cell Transplantation | 2 | 2021 | 97 | 0.380 |
Why?
| | Recurrence | 6 | 2023 | 1013 | 0.370 |
Why?
| | Infant | 14 | 2022 | 8377 | 0.350 |
Why?
| | Leukemia | 2 | 2020 | 213 | 0.330 |
Why?
| | Apoptosis | 5 | 2014 | 2639 | 0.320 |
Why?
| | Child, Preschool | 12 | 2022 | 9875 | 0.320 |
Why?
| | Leukemia, T-Cell | 1 | 2006 | 5 | 0.310 |
Why?
| | Lymphoma, T-Cell | 1 | 2006 | 17 | 0.310 |
Why?
| | Cell Line, Tumor | 7 | 2016 | 2933 | 0.300 |
Why?
| | Humans | 43 | 2023 | 119016 | 0.300 |
Why?
| | Hyperglycemia | 2 | 2020 | 340 | 0.290 |
Why?
| | Adolescent | 16 | 2022 | 19192 | 0.290 |
Why?
| | Betaine | 2 | 2019 | 63 | 0.290 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2010 | 707 | 0.280 |
Why?
| | Retrospective Studies | 14 | 2023 | 12249 | 0.270 |
Why?
| | Young Adult | 10 | 2022 | 11181 | 0.260 |
Why?
| | Transplantation, Autologous | 2 | 2019 | 199 | 0.220 |
Why?
| | Mice | 10 | 2019 | 15850 | 0.220 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 51 | 0.220 |
Why?
| | Treatment Outcome | 7 | 2021 | 9492 | 0.210 |
Why?
| | Siblings | 2 | 2019 | 275 | 0.210 |
Why?
| | Hematologic Neoplasms | 1 | 2021 | 121 | 0.200 |
Why?
| | Flow Cytometry | 3 | 2018 | 1171 | 0.200 |
Why?
| | Anemia, Aplastic | 1 | 2020 | 32 | 0.200 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2020 | 85 | 0.200 |
Why?
| | Fetal Blood | 1 | 2021 | 265 | 0.190 |
Why?
| | Neoplasms | 4 | 2020 | 2163 | 0.190 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 163 | 0.190 |
Why?
| | Histocompatibility | 1 | 2019 | 32 | 0.190 |
Why?
| | Signal Transduction | 6 | 2014 | 4919 | 0.190 |
Why?
| | Betaine-Homocysteine S-Methyltransferase | 1 | 2019 | 10 | 0.190 |
Why?
| | Animals | 12 | 2019 | 35392 | 0.180 |
Why?
| | Taurine | 1 | 2019 | 43 | 0.180 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2019 | 82 | 0.180 |
Why?
| | Molecular Targeted Therapy | 2 | 2013 | 382 | 0.180 |
Why?
| | WT1 Proteins | 1 | 2018 | 12 | 0.180 |
Why?
| | Male | 16 | 2021 | 61786 | 0.180 |
Why?
| | Multiple Myeloma | 1 | 2019 | 95 | 0.170 |
Why?
| | Cell Survival | 5 | 2014 | 1137 | 0.170 |
Why?
| | Female | 15 | 2021 | 64422 | 0.160 |
Why?
| | Central Nervous System Neoplasms | 1 | 2019 | 127 | 0.160 |
Why?
| | Antigens, CD19 | 3 | 2022 | 99 | 0.160 |
Why?
| | Calcineurin Inhibitors | 1 | 2017 | 66 | 0.160 |
Why?
| | Polyploidy | 1 | 2016 | 24 | 0.160 |
Why?
| | Cell Proliferation | 3 | 2016 | 2382 | 0.150 |
Why?
| | Neuroblastoma | 1 | 2017 | 133 | 0.150 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2014 | 173 | 0.150 |
Why?
| | Infant, Newborn | 4 | 2019 | 5203 | 0.150 |
Why?
| | Methotrexate | 1 | 2017 | 244 | 0.150 |
Why?
| | Mice, Nude | 2 | 2014 | 704 | 0.150 |
Why?
| | Incidence | 2 | 2019 | 2494 | 0.140 |
Why?
| | Cellular Senescence | 1 | 2016 | 147 | 0.140 |
Why?
| | Mice, Transgenic | 3 | 2013 | 2135 | 0.140 |
Why?
| | Gene Knockdown Techniques | 3 | 2013 | 323 | 0.140 |
Why?
| | African Americans | 1 | 2021 | 954 | 0.140 |
Why?
| | Pentacyclic Triterpenes | 1 | 2014 | 13 | 0.140 |
Why?
| | Cell Death | 1 | 2016 | 341 | 0.140 |
Why?
| | Neoplasm Invasiveness | 2 | 2014 | 457 | 0.140 |
Why?
| | Adult | 10 | 2023 | 32799 | 0.130 |
Why?
| | Adenine | 1 | 2016 | 256 | 0.130 |
Why?
| | Hypoglycemia | 1 | 2019 | 397 | 0.130 |
Why?
| | Phosphorylation | 3 | 2014 | 1754 | 0.130 |
Why?
| | Health Services Accessibility | 1 | 2021 | 812 | 0.130 |
Why?
| | Piperazines | 1 | 2016 | 330 | 0.130 |
Why?
| | Critical Illness | 1 | 2019 | 627 | 0.130 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2014 | 96 | 0.130 |
Why?
| | Enzyme Activation | 2 | 2016 | 961 | 0.130 |
Why?
| | Transplantation, Homologous | 3 | 2020 | 478 | 0.120 |
Why?
| | Intercellular Signaling Peptides and Proteins | 3 | 2016 | 375 | 0.120 |
Why?
| | Whole-Body Irradiation | 1 | 2012 | 77 | 0.110 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2011 | 31 | 0.110 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2011 | 80 | 0.110 |
Why?
| | Chemokine CCL4 | 1 | 2011 | 21 | 0.110 |
Why?
| | Oncogene Proteins | 2 | 2010 | 63 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2014 | 464 | 0.110 |
Why?
| | Tumor Cells, Cultured | 2 | 2010 | 1008 | 0.100 |
Why?
| | Interleukin-1alpha | 1 | 2011 | 58 | 0.100 |
Why?
| | Blood Glucose | 1 | 2020 | 1939 | 0.100 |
Why?
| | Interleukin-17 | 1 | 2011 | 96 | 0.100 |
Why?
| | Chronic Disease | 3 | 2023 | 1700 | 0.100 |
Why?
| | Thymus Neoplasms | 1 | 2010 | 22 | 0.100 |
Why?
| | Thymoma | 1 | 2010 | 33 | 0.100 |
Why?
| | Liver | 1 | 2019 | 1873 | 0.100 |
Why?
| | RNA Interference | 1 | 2011 | 500 | 0.090 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2010 | 198 | 0.090 |
Why?
| | Drug Delivery Systems | 2 | 2009 | 337 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2197 | 0.090 |
Why?
| | Survivors | 1 | 2012 | 423 | 0.090 |
Why?
| | Interleukin-1beta | 1 | 2011 | 418 | 0.090 |
Why?
| | Quality of Life | 1 | 2019 | 2356 | 0.080 |
Why?
| | Allografts | 2 | 2018 | 121 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2011 | 733 | 0.080 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2006 | 15 | 0.080 |
Why?
| | Gene Expression | 1 | 2011 | 1550 | 0.070 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2014 | 786 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1272 | 0.070 |
Why?
| | Survival Analysis | 2 | 2020 | 1420 | 0.070 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1325 | 0.070 |
Why?
| | DNA Primers | 1 | 2006 | 578 | 0.070 |
Why?
| | Cohort Studies | 3 | 2019 | 5129 | 0.060 |
Why?
| | Mice, Inbred C57BL | 3 | 2013 | 5227 | 0.060 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2016 | 1216 | 0.060 |
Why?
| | Vidarabine | 1 | 2022 | 27 | 0.060 |
Why?
| | Oxidative Stress | 1 | 2009 | 1239 | 0.060 |
Why?
| | Macrophages | 1 | 2009 | 1340 | 0.060 |
Why?
| | Base Sequence | 1 | 2006 | 2280 | 0.060 |
Why?
| | Risk Factors | 3 | 2020 | 9266 | 0.050 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2021 | 844 | 0.050 |
Why?
| | Gene Expression Regulation, Leukemic | 2 | 2013 | 59 | 0.050 |
Why?
| | Apoptosis Regulatory Proteins | 2 | 2014 | 215 | 0.050 |
Why?
| | Hematopoiesis | 1 | 2021 | 180 | 0.050 |
Why?
| | Tumor Burden | 2 | 2014 | 289 | 0.050 |
Why?
| | Melphalan | 1 | 2019 | 34 | 0.050 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2019 | 12 | 0.050 |
Why?
| | Severe Combined Immunodeficiency | 1 | 2019 | 20 | 0.050 |
Why?
| | Cost of Illness | 1 | 2021 | 300 | 0.050 |
Why?
| | Graft Survival | 1 | 2021 | 473 | 0.050 |
Why?
| | T-Lymphocytes | 2 | 2023 | 1835 | 0.040 |
Why?
| | Prognosis | 2 | 2017 | 3592 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2019 | 2862 | 0.040 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2019 | 205 | 0.040 |
Why?
| | Autografts | 1 | 2017 | 38 | 0.040 |
Why?
| | Cause of Death | 1 | 2019 | 390 | 0.040 |
Why?
| | Mortality | 1 | 2019 | 330 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2018 | 692 | 0.040 |
Why?
| | Outpatients | 1 | 2019 | 288 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2019 | 774 | 0.040 |
Why?
| | United States | 2 | 2023 | 12886 | 0.040 |
Why?
| | Neural Stem Cells | 1 | 2016 | 105 | 0.040 |
Why?
| | Lung Diseases, Interstitial | 1 | 2019 | 403 | 0.030 |
Why?
| | Dacarbazine | 1 | 2014 | 112 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1874 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 1011 | 0.030 |
Why?
| | Risk | 1 | 2017 | 956 | 0.030 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2013 | 159 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 328 | 0.030 |
Why?
| | Registries | 1 | 2019 | 1962 | 0.030 |
Why?
| | Phosphotransferases | 1 | 2010 | 33 | 0.030 |
Why?
| | Thymectomy | 1 | 2010 | 16 | 0.030 |
Why?
| | Prospective Studies | 1 | 2022 | 6565 | 0.020 |
Why?
| | Remission Induction | 1 | 2010 | 271 | 0.020 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2010 | 336 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 3894 | 0.020 |
Why?
| | Mice, SCID | 1 | 2009 | 372 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2009 | 597 | 0.020 |
Why?
| | Tumor Microenvironment | 1 | 2010 | 423 | 0.020 |
Why?
| | Radiography | 1 | 2010 | 862 | 0.020 |
Why?
| | Cognition Disorders | 1 | 2012 | 594 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2012 | 1141 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2010 | 1230 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2010 | 941 | 0.020 |
Why?
| | Jurkat Cells | 1 | 2006 | 140 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2006 | 89 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2010 | 514 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2008 | 296 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2010 | 1022 | 0.020 |
Why?
| | Sex Factors | 1 | 2010 | 1993 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 1089 | 0.020 |
Why?
| | Cell Line | 1 | 2009 | 2937 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1430 | 0.010 |
Why?
| | Middle Aged | 1 | 2021 | 29243 | 0.010 |
Why?
| | Models, Biological | 1 | 2008 | 1814 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1472 | 0.010 |
Why?
|
|
Keating's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|